Antipsychotic drug toxicology in children

Bibliography

• Comer JS, Olfson M, Mojtabai R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 2010;49(10):1001-10
   PubMed Web of Science ®Google Scholar
• Verdoux H, Tournier M, Begaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121(1):4-10
   PubMed Web of Science ®Google Scholar
• Mattai AK, Hill JL, Lenroot RK. Treatment of early-onset schizophrenia. Curr Opin Psychiatry 2010;23(4):304-10
   PubMed Web of Science ®Google Scholar
• Danielyan A, Kowatch RA. Management options for bipolar disorder in children and adolescents Paediatr Drugs 2005;7(5):277-94
   Google Scholar
• Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18(3):250-60
   PubMedGoogle Scholar
• Vitiello B, Correll C, van Zwieten-Boot B, Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009;19(9):629-35
   PubMed Web of Science ®Google Scholar
• McConville BJ, Sorter MT. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry 2004;65(6):20-9
   PubMedGoogle Scholar
• Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004;27(14):1135-56
   PubMed Web of Science ®Google Scholar
• Dubois D. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Curr Opin Pediatr 2005;17(2):227-33
   PubMed Web of Science ®Google Scholar
• Krebs M, Leopold K, Hinzpeter A, Schaefer M. Current schizophrenia drugs: efficacy and side effects. Expert Opin Pharmacother 2006;7(8):1005-16
   PubMed Web of Science ®Google Scholar
• Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry 2005;66(7):29-40
   PubMedGoogle Scholar
• Kapetanovic S, Simpson GM. Review of antipsychotics in children and adolescents. Expert Opin Pharmacother 2006;7:1871-85
   PubMed Web of Science ®Google Scholar
• Fraguas D, Correll CU, Merchan-Naranjo J, Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 2010; In press
   Google Scholar
• Correll CU, Kane JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007;17(5):647-56
   PubMed Web of Science ®Google Scholar
• Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 2007, Issue 1. Art. No.: CD005040. DOI: 10.1002/14651858.CD005040.pub2
   PubMed Web of Science ®Google Scholar
• Findling RL. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 2008;69(4):9-14
   PubMedGoogle Scholar
• Correll CU, Manu P, Olshanskiy V, Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302(16):1765-73
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 2008;162(10):929-35
   PubMed Web of Science ®Google Scholar
• British national formulary for children. BMJ, Pharmaceutical Press and RCPCH Publications Ltd, 2010. Available from: http:www.bnfc.org [Last accessed 30 November 2010]
   Google Scholar
• Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(1):9-20
   PubMed Web of Science ®Google Scholar
• Pichini S, Papaseit E, Joya X, Pharmacokinetics and therapeutic drug monitoring of psychotropic drug in pediatrics. Ther Drug Monit 2009;31(3):283-318
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1(3):447-71
   PubMedGoogle Scholar
• Mehler-Wex C, Kolch M, Kirchheiner J, Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009;3(1):14
   PubMedGoogle Scholar
• Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy 2009;29(6):680-90
   PubMed Web of Science ®Google Scholar
• Cranswick NE. Pharmacokinetics and Pharmacodynamics. In: Jacqz-Aigrain E, Choonara I, editors, Paediatric Clinical Pharmacology. Taylor & Francis Group, New York; 2006
   Google Scholar
• Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393-414
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9(5):410-18
   PubMed Web of Science ®Google Scholar
• Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58(7):871-85
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients. Psychopharmacol Bull 2007;40(1):77-97
   PubMed Web of Science ®Google Scholar
• Spina E, De Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100(1):4-22
   PubMed Web of Science ®Google Scholar
• Macleod S. Therapeutic drug monitoring in pediatrics: how do children differ? Ther Drug Monit 2010;32:253-6
   PubMed Web of Science ®Google Scholar
• Baumann P, Hiemke C, Ulrich S, Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 2004;26(2):167-70
   PubMed Web of Science ®Google Scholar
• Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000;22(1):118-21
   PubMed Web of Science ®Google Scholar
• De Leon J, Susce MT, Pan RM, The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. Clin Psychiatry 2005;66(1):15-27
   PubMed Web of Science ®Google Scholar
• Brockmoller J, Kirchheiner J, Schmider J, The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002;72(4):438-52
   PubMed Web of Science ®Google Scholar
• Llerena A, Berecz R, De La Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002;16(4):361-4
   PubMed Web of Science ®Google Scholar
• Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol 1998;8(3):161-74
   PubMed Web of Science ®Google Scholar
• Blake MJ, Gaedigk A, Pearce RE, Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81(4):510-16
   PubMed Web of Science ®Google Scholar
• Prows CA, Nick Tg, Saldana SN, Drug-metabolizing enzyme genotypes and aggressive behavior treatment response in hospitalized pediatric psychiatric patients. Child Adolesc Psychopharmacol 2009;19(4):385-94
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Gurwitz D, De Leon J, CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 2009;10(4):685-99
   PubMed Web of Science ®Google Scholar
• Gerbino-Rosen G, Roofeh D, Tompkins DA, Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44(10):1024-31
   PubMed Web of Science ®Google Scholar
• Morselli PL, Bianchetti G, Dugas M. Therapeutic drug monitoring of psychotropic drugs in children. Pediatr Pharmacol 1983;3(3-4):149-56
   PubMedGoogle Scholar
• Rivera-Calimlim L, Griesbach PH, Perlmutter R. Plasma chlorpromazine concentrations in children with behavioral disorders and mental illness. Clin Pharmacol Ther 1979;26(1):114-21
   PubMed Web of Science ®Google Scholar
• Rivera-Calimlim L. Problems in therapeutic blood monitoring of chlorpromazine. Ther Drug Monit 1982;4(1):41-9
   PubMed Web of Science ®Google Scholar
• Furlanut M, Benetello P, Baraldo M, Chlorpromazine disposition in relation to age in children. Clin Pharmacokinet 1990;18(4):329-31
   PubMed Web of Science ®Google Scholar
• Yoshii K, Kobayashi K, Tsumuji M, Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000;67(2):175-84
   PubMed Web of Science ®Google Scholar
• Frazier JA, Cohen LG, Jacobsen L, Clozapine pharmacokinetics in children and adolescents with childhood-onset schizophrenia. J Clin Psychopharmacol 2003;23(1):87-91
   PubMed Web of Science ®Google Scholar
• Wojcikowski J, Boksa J, Daniel WA. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver-A comparison with other phenothiazines. Biochem Pharmacol 2010;80(8):1252-9
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158(11):1774-82
   PubMed Web of Science ®Google Scholar
• Dorado P, Berecz R, Penas-Lledo EM, Llerena A. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin Drug Metab Toxicol 2007;3(1):9-19
   PubMed Web of Science ®Google Scholar
• Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998;34:227-63
   PubMed Web of Science ®Google Scholar
• Morselli PL, Bianchetti G, Durand G, Haloperidol plasma level monitoring in pediatric patients. Ther Drug Monit 1979;1(1):35-46
   PubMed Web of Science ®Google Scholar
• Morselli PL, Bianchetti G, Dugas M. Haloperidol plasma level monitoring in neuropsychiatric patients. Ther Drug Monit 1982;4(1):51-8
   PubMed Web of Science ®Google Scholar
• Piscitelli SC, Frazier JA, McKenna K, Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55(Suppl B):94-7
   PubMedGoogle Scholar
• Fang J, Mckay G, Song J, In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab Dispos 2001;29(12):1638-43
   PubMed Web of Science ®Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999;37(6):435-56
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang WH, Chang YC, Dose-dependent reduced haloperidol/haloperidol ratios: influence of patient-related variables. Psychiatry Res 1997;72(2):127-32
   PubMed Web of Science ®Google Scholar
• Tischler B, Patriasz K, Bberesford J, Bunting R. Experience with pericyazine in profoundly and severely retarded children. CMA J 1972;106:136-41
   PubMed Web of Science ®Google Scholar
• Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996;60:41-7
   PubMed Web of Science ®Google Scholar
• Jerling M, Dahl M-L, Aberg-Wistedt A, The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59(4):423-8
   PubMed Web of Science ®Google Scholar
• Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000;50(6):563-71
   PubMed Web of Science ®Google Scholar
• Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20(5):243-51
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009;2:CD006996
   PubMedGoogle Scholar
• Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry 2004;43(2):206-14
   PubMed Web of Science ®Google Scholar
• Degrauw RS, Li JZ, Gilbert DL. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Pediatr Neurol 2009;41(3):183-6
   PubMed Web of Science ®Google Scholar
• Sallee FR, Pollock BG, Stiller RL, Pharmacokinetics of pimozide in adults and children with Tourette's syndrome. J Clin Pharmacol 1987;27(10):776-81
   PubMed Web of Science ®Google Scholar
• McCreadie RG, Heykants JJ, Chalmers A, Anderson AM. Plasma pimozide profiles in chronic schizophrenics. Br J Clin Pharmacol 1979;7(5):533-4
   PubMed Web of Science ®Google Scholar
• Desta Z, Kerbusch T, Soukhova N, Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998;285(2):428-37
   PubMed Web of Science ®Google Scholar
• Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65(1):10-20
   PubMed Web of Science ®Google Scholar
• Flockhart DA, Drici MD, Kerbusch T, Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20(3):317-24
   PubMed Web of Science ®Google Scholar
• Caley CF, Weber SS. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 1995;29(2):152-60
   PubMed Web of Science ®Google Scholar
• The electronic Medicines Compendium (eMC) Rosemont Pharmaceuticals Limited, Yorkshire, UK. Available from: http://www.medicines.org.uk/emc/medicine/7909# [Last accessed 25 November 2010]
   Google Scholar
• Midha KK, Hawes EM, Hubbard JW, Pharmacokinetic study of trifluoperazine in two ethnic populations. Psychopharmacology 1988;95(3):333-8
   PubMed Web of Science ®Google Scholar
• Mckeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004;18(13):933-56
   PubMed Web of Science ®Google Scholar
• Varol Tas F, Guvenir T. Amisulpride treatment of adolescent patients with schizophrenia or schizo-affective disorders. Eur Child Adolesc Psychiatry 2009;18(8):511-13
   PubMed Web of Science ®Google Scholar
• Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004;14:245-50
   PubMed Web of Science ®Google Scholar
• Muller MJ, Regenbogen B, Hartter S, Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007;41(8):673-9
   PubMed Web of Science ®Google Scholar
• Muller MJ, Eich FX, Regenbogen B, Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 2009;23(3):278-86
   PubMed Web of Science ®Google Scholar
• Findling RL, Frazier JA, Gerbino-Rosen G, Is there a role for clozapine in the treatment of children and adolescents? J Am Acad Child Adolesc Psychiatry 2007;46:423-8
   PubMed Web of Science ®Google Scholar
• Kumra S, Frazier JA, Jacobsen LK, Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53:1090-7
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008;63(5):524-9
   PubMed Web of Science ®Google Scholar
• Kumra S, Kranzler H, Gerbino-Rosen G, Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol 2008;18(4):307-16
   PubMed Web of Science ®Google Scholar
• Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. Psychiatr Pract 2005;11(5):289-301
   PubMedGoogle Scholar
• Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine: norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010;32(4):438-47
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Colasanti A, Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46(5):359-88
   PubMed Web of Science ®Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37(3):177-93
   PubMed Web of Science ®Google Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010;11(6):516-25
   PubMed Web of Science ®Google Scholar
• Findling RL, Mcnamara NK. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J Clin Psychiatry 2004;65(6):30-44
   PubMedGoogle Scholar
• Jensen PS, Buitelaar J, Pandina GJ, Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials. Eur Child Adolesc Psychiatry 2007;6(2):104-20
   Google Scholar
• Singh MK, Ketter TA, Chang KD. Typical antipsychotics for acute manic and mixed episodes in children and adolescents with bipolar disorder: efficacy and tolerability. Drugs 2010;70(4):433-42
   PubMed Web of Science ®Google Scholar
• McCormack PL. Olanzapine: in adolescents with schizophrenia or bipolar I disorder. CNS Drugs 2010;24(5):443-52
   PubMed Web of Science ®Google Scholar
• Frazier JA, McClellan J, Findling RL, Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristic. J Am Acad Child Adolesc Psychiatry 2007;46(8):979-88
   PubMed Web of Science ®Google Scholar
• Sikich L, Frazier JA, McClellan J, Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008;165(11):1420-31
   PubMed Web of Science ®Google Scholar
• Findling RL, Johnson JL, McClellan J, Double-blind maintenance safety and effectiveness findings from the Treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 2010;49(6):583-94
   PubMed Web of Science ®Google Scholar
• Alfaro CL, Wudarsky M, Nicolson R, Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol 2002;12(2):83-91
   PubMed Web of Science ®Google Scholar
• Grothe DR, Calis KA, Jacobsen L, Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia. J Clin Psychopharmacol 2000;20(2):220-5
   PubMed Web of Science ®Google Scholar
• Theisen FM, Haberhausen M, Schulz E, Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006;28(6):750-9
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008;30(1):108-12
   PubMed Web of Science ®Google Scholar
• Findling R. Use of quetiapine in children and adolescents. J Clin Psychiatry 2003;63:27-31
   Web of Science ®Google Scholar
• Findling RL, Reed MD, O'riordan MA, Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 2006;45(7):792-800
   PubMed Web of Science ®Google Scholar
• McConville BJ, Arvanitis LA, Thyrum PT, Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000;61:252-60
   PubMed Web of Science ®Google Scholar
• Devane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001;40(7):509-22
   PubMed Web of Science ®Google Scholar
• Gerlach M, Hunnerkopf R, Rothenhofer S, Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007;40(2):72-6
   PubMed Web of Science ®Google Scholar
• Winter HR, Earley WR, Hamer-Maansson JE, Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18(1):81-98
   PubMed Web of Science ®Google Scholar
• Scott LJ, Dhillon S. Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents. Paediatr Drugs 2007;9(5):343-54
   PubMedGoogle Scholar
• Lemmon ME, Gregas M, Jeste SS. Risperidone use in autism spectrum disorders: a retrospective review of a clinic-referred patient population. J Child Neurol 2010 Oct 6. doi: 10.1177/0883073810382143
   Google Scholar
• Anderson GM, Scahill L, McCracken JT, Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 2007;61(4):545-50
   PubMed Web of Science ®Google Scholar
• Calarge CA, Ellingrod VL, Acion L, Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009;19(5):373-82
   PubMed Web of Science ®Google Scholar
• Aman MG, Vinks A, Remmerie B, Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007;29(7):1476-86
   PubMed Web of Science ®Google Scholar
• Thyssen A, Vermeulen A, Fuseau E, Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 2010;49(7):465-78
   PubMed Web of Science ®Google Scholar
• Knegtering R, Baselmans P, Castelein S, Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162(5):1010-12
   PubMed Web of Science ®Google Scholar
• Troost Pw, Lahuis Be, Hermans MH, Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007;27(1):52-7
   PubMed Web of Science ®Google Scholar
• Delbello MP, Versavel M, Ice K, Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. Child Adolesc Psychopharmacol 2008;18(5):491-9
   PubMed Web of Science ®Google Scholar
• Penfold RB, Kelleher KJ, Wang W, Pediatric uptake of a newly available antipsychotic medication. Pediatrics 2010;125(3):475-82
   PubMed Web of Science ®Google Scholar
• Mcdougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41(8):921-7
   PubMed Web of Science ®Google Scholar
• Mcdougle CJ, Stigler KA, Erickson CA, Posey DJ. Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. J Clin Psychiatry 2008;69(4):15-20
   PubMedGoogle Scholar
• Sallee FR, Kurlan R, Goetz CG, Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;39:292-9
   PubMed Web of Science ®Google Scholar
• Biederman J, Mick E, Spencer T, A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 2007;9(8):888-94
   PubMed Web of Science ®Google Scholar
• Versavel M, Delbello MP, Ice K, Dosing Study in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder. Neuropsychopharmacology 2005;30(1):S122-3
   Google Scholar
• Blair J, Scahill L, State M, Martin A. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study. J Am Acad Child Adolesc Psychiatry 2005;44:73-9
   PubMed Web of Science ®Google Scholar
• Elbe D, Carandang CG. Focus on ziprasidone: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2008;17(4):220-9
   PubMedGoogle Scholar
• Scahill L, Blair J, Leckman JF, Martin A. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone. J Psychopharmacol 2005;19(2):205-6
   PubMed Web of Science ®Google Scholar
• Gutgesell H, Atkins D, Barst R, AHA Scientific Statement: cardiovascular monitoring of children and adolescents receiving psychotropic drugs. J Am Acad Child Adolesc Psychiatry 1999;38:1047-50
   PubMed Web of Science ®Google Scholar
• Sallee FR, Miceli JJ, Tensfeldt T, Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006;45:720-8
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64(15):1715-36
   PubMed Web of Science ®Google Scholar
• Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007;8(6):612-22
   PubMed Web of Science ®Google Scholar
• Findling RL, Kauffman R, Sallee FR, An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. Child Adolesc Psychopharmacol 2009;19(4):431-9
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008;30(4):462-6
   PubMed Web of Science ®Google Scholar
• Del Bello MP, Correll CU. Primum non nocere: balancing the risks and benefits of prescribing psycotropic medications for youth with bipolar disorder. Bipolar Disord 2010;12:113-15
   PubMed Web of Science ®Google Scholar
• Koelch M, Schnoor K, Fegert JM. Ethical issues in psychopharmacology of children and adolescents. Curr Opinion Psychiatry 2008;21:598-605
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24(6):412-24
   PubMed Web of Science ®Google Scholar
• Moreno C, Merchan-Naranjo J, Alvarez M, Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsycotic diagnoses. Bipolar Disord 2010;12:172-84
   PubMed Web of Science ®Google Scholar